Sichuan Kelun-Biotech Biopharmaceutical revenue and financials
In the fiscal year ended December 2025, Sichuan Kelun-Biotech Biopharmaceutical reported revenue of ¥2.06B (+6.46% year over year). The net loss was ¥381.97M.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +6.46%
- 2025 vs 2024
- Net margin
- -18.6%
- 2024: -13.8%
How Sichuan Kelun-Biotech Biopharmaceutical is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 36.8% a year on average over the last 3 years
Compound annual growth rate: from ¥803.93M in 2022 to ¥2.06B in 2025.
Revenue has grown for 4 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin rose from −49.0% to −20.4%
Operating income over revenue, 2022 → 2025: 28.6 percentage points.
Shares outstanding up 141.4% in 3 years
Average diluted shares, 2022 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 0 of 5 fiscal years
Positive net income, fiscal years 2021–2025.
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 2,058 | 1,933 | 1,540 | 804 | 32.3 |
| Cost of revenue | 579 | 659 | 781 | 277 | 23.1 |
| Gross profit | 1,479 | 1,274 | 759 | 527 | 9.3 |
| Selling, general and administrative | 654 | 346 | 201 | 93.0 | 91.0 |
| Research and development | 1,320 | 1,206 | 1,031 | 846 | 728 |
| Operating income | -420 | -279 | -454 | -394 | -795 |
| EBIT | -420 | -279 | -454 | -394 | -795 |
| EBITDA | -365 | -231 | -420 | -368 | -776 |
| Interest expense | 6.2 | 3.8 | 84.3 | 149 | 113 |
| Pre-tax income | -356 | -143 | -468 | -567 | -890 |
| Income tax | 26.2 | 124 | 106 | 48.7 | — |
| Net income | -382 | -267 | -574 | -616 | -890 |
| Net income to common shareholders | -382 | -267 | -522 | -548 | -823 |
| Basic EPS | -1.66 | -1.20 | -2.84 | -5.74 | -8.90 |
| Diluted EPS | -1.66 | -1.20 | -2.84 | -5.74 | -8.90 |
| Average shares (basic) | 231 | 222 | 184 | 95.5 | 92.5 |
| Average shares (diluted) | 231 | 222 | 184 | 95.5 | 92.5 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 978 | 1,107 | 950 | 550 | 1,383 | 494 | 1,046 | 459 | 345 |
| Cost of revenue | 241 | 289 | 290 | 353 | 306 | 439 | 342 | 157 | 120 |
| Gross profit | 737 | 819 | 660 | 197 | 1,077 | 55.4 | 704 | 302 | 225 |
| Selling, general and administrative | 470 | 401 | 253 | 239 | 107 | 113 | 88.4 | 51.7 | 41.4 |
| Research and development | 768 | 708 | 612 | 554 | 652 | 541 | 490 | 502 | 344 |
| Operating income | 219 | -223 | -197 | -647 | 368 | -551 | 97.8 | -236 | -158 |
| EBIT | 219 | -223 | -197 | -647 | 368 | -551 | 97.8 | -236 | -158 |
| EBITDA | 254 | -195 | -170 | -622 | 391 | -533 | 113 | -221 | -147 |
| Interest expense | 2.1 | 3.1 | 3.0 | 1.3 | 2.5 | 5.6 | 78.7 | 76.3 | 72.5 |
| Pre-tax income | 248 | -180 | -176 | -552 | 409 | -509 | 41.3 | -321 | -246 |
| Income tax | -140 | 56.6 | -30.4 | 25.2 | 99.0 | 34.0 | 72.4 | 24.1 | 24.6 |
| Net income | 388 | -237 | -145 | -577 | 310 | -543 | -31.1 | -345 | -271 |
| Net income to common shareholders | 388 | -237 | -145 | -577 | 310 | -497 | -25.4 | -307 | -241 |
| Basic EPS | 1.66 | -1.02 | -0.64 | -2.59 | 1.41 | -2.31 | -0.17 | -3.22 | -2.52 |
| Diluted EPS | 1.66 | -1.02 | -0.64 | -2.59 | 1.41 | -2.31 | -0.17 | -3.22 | -2.52 |
| Average shares (basic) | 233 | 233 | 228 | 223 | 220 | 215 | 152 | 95.5 | 95.5 |
| Average shares (diluted) | 233 | 233 | 228 | 223 | 220 | 215 | 152 | 95.5 | 95.5 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 5,989 | 4,268 | 3,510 | 993 | 813 |
| Current assets | 5,149 | 3,493 | 2,807 | 332 | 298 |
| Cash and equivalents | 3,244 | 1,337 | 1,529 | 93.0 | 81.8 |
| Short-term investments | 293 | 284 | 326 | — | — |
| Receivables | 291 | 244 | 124 | 104 | 70.6 |
| Inventory | 241 | 111 | 63.0 | 52.6 | 50.7 |
| Net property, plant and equipment | 758 | 758 | 693 | 648 | 474 |
| Other intangible assets | 1.1 | 2.6 | 1.3 | 3.2 | 0.5 |
| Long-term investments | 70.1 | — | — | — | — |
| Current liabilities | 1,004 | 810 | 1,110 | 4,167 | 3,445 |
| Accounts payable | 426 | 291 | 404 | 327 | 325 |
| Total debt | 88.4 | 127 | 59.9 | 124 | 2.9 |
| Total liabilities | 1,121 | 959 | 1,180 | 4,219 | 3,457 |
| Total equity (incl. minority) | 4,867 | 3,309 | 2,329 | -3,226 | -2,644 |
| Retained earnings | -4,705 | -4,323 | -4,056 | -3,482 | -2,866 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6,322 | 5,989 | 5,953 | 4,268 | 3,835 | 3,510 | 2,562 | 993 | — |
| Current assets | 5,512 | 5,149 | 5,193 | 3,493 | 3,158 | 2,807 | 1,908 | 332 | — |
| Cash and equivalents | 2,776 | 3,244 | 3,103 | 1,337 | 2,130 | 1,529 | 587 | 93.0 | — |
| Short-term investments | 123 | 293 | 559 | 284 | 383 | 326 | 270 | — | — |
| Receivables | 420 | 291 | 405 | 244 | 163 | 124 | 77.2 | 104 | — |
| Inventory | 272 | 241 | 200 | 111 | 60.9 | 63.0 | 90.7 | 52.6 | — |
| Net property, plant and equipment | 738 | 758 | 741 | 758 | 664 | 693 | 644 | 648 | — |
| Other intangible assets | 0.2 | 1.1 | 1.7 | 2.6 | 2.5 | 1.3 | 3.1 | 3.2 | — |
| Long-term investments | 68.1 | 70.1 | — | — | — | — | — | — | — |
| Current liabilities | 870 | 1,004 | 790 | 810 | 554 | 1,110 | 3,032 | 4,167 | — |
| Accounts payable | 515 | 426 | 365 | 291 | 424 | 404 | 309 | 327 | — |
| Total debt | 81.4 | 88.4 | 131 | 127 | 38.2 | 59.9 | 85.7 | 124 | — |
| Total liabilities | 985 | 1,121 | 939 | 959 | 626 | 1,180 | 3,087 | 4,219 | — |
| Total equity (incl. minority) | 5,337 | 4,867 | 5,014 | 3,309 | 3,209 | 2,329 | -525 | -3,226 | — |
| Retained earnings | -4,317 | -4,705 | -4,468 | -4,323 | -3,746 | -4,056 | -3,513 | -3,482 | — |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -180 | -430 | 59.6 | -271 | -486 |
| Depreciation and amortization | 100 | 91.4 | 75.1 | 67.4 | 22.9 |
| Capital expenditure | -126 | -77.5 | -81.0 | -33.7 | -94.1 |
| Investing cash flow | 411 | -822 | -1,025 | -32.2 | -94.4 |
| Financing cash flow | 1,728 | 1,037 | 2,382 | 313 | 647 |
| Debt issued | — | — | 0.0 | 363 | 225 |
| Debt repaid | -43.2 | -54.6 | -461 | -46.6 | -72.0 |
| Effect of exchange rates | -51.5 | 22.3 | 19.4 | 0.7 | -1.4 |
| Net change in cash | 1,907 | -192 | 1,436 | 11.2 | 65.6 |
| Free cash flow | -306 | -507 | -21.4 | -305 | -580 |
| Levered free cash flow | -182 | -411 | -439 | -175 | — |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 339 | 193 | -373 | -361 | -68.9 | -412 | 471 | -116 | -155 |
| Depreciation and amortization | 57.7 | 51.3 | 49.1 | 46.9 | 44.5 | 39.1 | 36.0 | 35.4 | 31.9 |
| Capital expenditure | -26.5 | -84.4 | -41.3 | -42.2 | -35.2 | -48.9 | -32.1 | -26.5 | -7.2 |
| Investing cash flow | -782 | 43.2 | 368 | -1,002 | 180 | 6.2 | -1,032 | -29.4 | -2.7 |
| Financing cash flow | -13.8 | -46.3 | 1,774 | 567 | 470 | 1,338 | 1,044 | -18.4 | 332 |
| Debt issued | — | — | — | — | — | — | — | 0.0 | 363 |
| Debt repaid | -11.7 | -40.4 | -2.8 | -34.2 | -20.4 | -29.1 | -432 | -16.1 | -30.5 |
| Effect of exchange rates | -11.0 | -48.8 | -2.7 | 1.6 | 20.7 | 8.8 | 10.6 | -2.0 | 2.7 |
| Net change in cash | -468 | 141 | 1,766 | -794 | 602 | 942 | 494 | -166 | 177 |
| Free cash flow | 312 | 109 | -414 | -403 | -104 | -460 | 439 | -142 | -162 |
| Levered free cash flow | -15.6 | 211 | -393 | -156 | -254 | -2,170 | 1,732 | -175 | — |
Financial statements of similar companies
Companies in the group: same industry, similar size
